Bituximab was first approved for market by the US Food and Drug Administration (FDA) in February 2018, and has since been approved in multiple regions such as the European Union and Japan. In August 2019, Bituowei was approved in China and officially listed in China in January 2020.

1、 Drug name

1. Common name: Biconazole tablets

1. Product Name: Biktarvy/Biktarvy

1. Main ingredients: A fixed dose compound preparation composed of bikinamivir, emtricitabine, and propafenone.

2、 Indications

1. Used to treat adult patients with human immunodeficiency virus type 1 (HIV-1) infection.

2. Applicable to: newly diagnosed patients (without history of antiretroviral therapy); Or for patients with virological suppression (HIV-1 RNA<50 copies/mL) and no history of treatment failure, and no known resistance related substitution mutations to any component of this product, to replace the current antiretroviral regimen.

3、 Specifications and characteristics

Each tablet contains: 50 milligrams of bikinamivir (calculated as 52.5 milligrams of bikinamivir sodium), 200 milligrams of emtricitabine, and 25 milligrams of propafenone (calculated as 28 milligrams of propafenone fumarate).

4、 Main components

Active ingredients: Bicentecavir (HIV-1 integrase chain transfer inhibitor INSTI), Emtricitabine (HIV-1 nucleoside reverse transcriptase inhibitor NRTI), Propenovir (HIV-1 nucleoside reverse transcriptase inhibitor NRTI).

5、 Usage and dosage

1. Recommended dosage: once a day, one tablet each time.

2. Usage: Can be taken with food or on an empty stomach.

6、 Dose adjustment

1. Renal dysfunction: Not recommended for estimating creatinine clearance rates below 30 milliliters per minute in patients.

2. Liver function impairment: Not recommended for patients with severe liver injury (Child Pugh C grade).

7、 Medication precautions

1. Relationship with food: can be taken with food or on an empty stomach.

2. Interval between taking multivalent cationic drugs (such as antacids, calcium/iron supplements):

3. Aluminum/magnesium containing antacids or calcium supplements: Bituximab should be taken on an empty stomach and taken 2 hours before or after it. It is not recommended to take it together with Bituximab or within 2 hours after taking it.

4. Supplements containing calcium or iron: can be taken with meals along with Betamethasone. It is not recommended to take it on an empty stomach or within 2 hours after taking it.

5. Omission: Medication should be taken regularly to avoid missed doses. If a missed dose is found, it should be taken as soon as possible. If it is close to the next dose, skip this time and do not double the dosage.

6. Vomiting: If vomiting occurs shortly after taking medication, please consult a doctor for specific treatment methods.

7. Warning for drug withdrawal: For patients with hepatitis B virus (HBV) infection, discontinuation of Pitorvir may lead to severe acute exacerbation of hepatitis B. Do not stop taking medication without authorization, and closely monitor liver function after stopping medication.

8、 Medication for special populations

1. Pregnancy period: Human data is limited, it is recommended to inform the doctor. There is an antiretroviral pregnancy registry.

2. Breastfeeding period: HIV-1 infected mothers should not breastfeed to avoid virus transmission and potential drug exposure risks.

3. Children: The safety and efficacy of patients under 18 years old have not been established.

4. Elderly people: Due to limited data, caution is needed.

5. Liver/kidney dysfunction: refer to the "Dose Adjustment" section.

9、 Adverse reactions

1. The most common adverse reactions (incidence ≥ 5%, all grades) are diarrhea, nausea, and headache.

2. Serious Warning and Precautions:

3. Acute exacerbation of hepatitis in patients with combined HBV infection after discontinuation of medication.

4. Immune reconstitution syndrome.

5. New or worsening renal dysfunction (including Fanconi syndrome) requires regular monitoring of renal function.

6. Lactic acidosis/severe liver enlargement with fatty degeneration (rare but potentially fatal).

10、 Contraindications

1. Do not use it in combination with Doxetine (as it may cause an increase in blood drug concentration and lead to serious incidents).

2. It is prohibited to use it in combination with rifampicin (as it can significantly reduce the blood concentration of bikinamivir, leading to loss of efficacy and possible development of drug resistance).

11、 Drug interactions

1. This product is a complete treatment plan and is not recommended to be used in combination with other anti-HIV-1 drugs.

Important interacting drugs include:

2. Anticonvulsant drugs (such as carbamazepine, phenytoin, etc.) and St. John's wort: may reduce the efficacy of metoprolol and are not recommended for combination.

3. Leflunitine and Leflunitine: It is not recommended to use them together.

4. Drugs excreted through organic cation transporter 2 (OCT2) and multi toxin efflux transporter 1 (MATE1) (such as dofetide, contraindicated).

5. The combination of nephrotoxic drugs (such as high-dose or repeated use of nonsteroidal anti-inflammatory drugs) or drugs actively secreted by the kidneys (such as acyclovir, valacyclovir, etc.) may increase the risk of adverse reactions.

6. The combination of metoprolol and metoprolol should be evaluated for its advantages and disadvantages based on its instructions.

12、 Storage method

1. Store below 30 ° C (86 ° F).

2. Keep the container tightly sealed.

3. Distribute only in the original packaging container.

Biktarvyinformation